Therapy in Multiple Sclerosis - Coming of Age.

In this issue of the Journal, Chitnis and colleagues report a phase 3 clinical trial of two drugs to treat pediatric multiple sclerosis, defined as occurring in persons younger than 18 years of age...

• Publication year

  2018

• Venue

  New England Journal of Medicine

• Publication date

  2018-09-12

• Fields of study

  Medicine

• Identifiers
  DOI 10.1056/NEJMe1810019PMID 30207922
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Trial of Fingolimod versus Interferon Beta‐1a in Pediatric Multiple Sclerosis

  2018cited by this paper
• Five years before multiple sclerosis onset: Phenotyping the prodrome

  2018cited by this paper
• Pediatric Neuromyelitis Optica Spectrum Disorders

  2018cited by this paper
• “No evident disease activity”: The use of combined assessments in the management of patients with multiple sclerosis

  2017cited by this paper
• Fingolimod induces neuronal-specific gene expression with potential neuroprotective outcomes in maturing neuronal progenitor cells exposed to HIV

  2017cited by this paper
• Sphingosine 1-phosphate receptor modulation suppresses pathogenic astrocyte activation and chronic progressive CNS inflammation

  2017cited by this paper
• Sphingosine-1-Phosphate Receptors in the Central Nervous and Immune Systems.

  2016cited by this paper
• Environmental and genetic factors in pediatric inflammatory demyelinating diseases

  2016cited by this paper
• Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial.

  2016cited by this paper
• FTY720 modulates human oligodendrocyte progenitor process extension and survival

  2008cited by this paper

• Functioning Profiles of Young People with MS in Inpatient Rehabilitation: Data from the National Rehabilitation Reporting System in Canada.

  2020cites this paper
• For Your Patients-Pediatric Multiple Sclerosis

  2018cites this paper